Search Within

Brigit McLaughlin

Formats
  1. Meeting Abstract (8)
  2. Journal Article (6)
Groups
  1. Department of Medicine (14)
  2. Genitourinary Oncology Service (14)
  3. Solid Tumor Oncology Division (14)
  4. Epidemiology and Biostatistics (9)
  5. Biostatistics Service (7)
  6. Molecular Imaging and Therapy Service (5)

More Groups

People
  1. Howard Scher (14)
  2. Martin Fleisher (12)
  3. Nicole Schreiber (11)
  4. Glenn Heller (7)
  5. Daniel Danila (4)
  6. Hebert Vargas Alvarez (4)

More People

Years
  1. 2020 (1)
  2. 2018 (2)
  3. 2017 (6)
  4. 2016 (5)
Publications
  1. Journal of Clinical Oncology (6)
  2. Annals of Oncology (2)
  3. JAMA Oncology (2)
  4. JCO Precision Oncology (2)
  5. Cancer Research (1)
  6. European Urology (1)
Publishers
  1. American Society of Clinical Oncology (8)
  2. American Medical Association (2)
  3. Oxford University Press (2)
  4. American Association for Cancer Research (1)
  5. Elsevier Science, Inc. (1)

Results (14)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dickkopf-1 can lead to immune evasion in metastatic castration-resistant prostate cancer
    Journal Article

    Wise, D. R.; Schneider, J. A.; Armenia, J.; Febles, V. A.; McLaughlin, B.; Brennan, R.; Thoren, K. L.; Abida, W.; Sfanos, K. S.; De Marzo, A. M.; more...
    JCO Precision Oncology (2020)

    Fulltext@MSK | Save
  • Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Scher, H. I.; Graf, R. P.; Schreiber, N. A.; Winquist, E.; McLaughlin, B.; Lu, D.; Orr, S.; Fleisher, M.; Lowes, L.; Anderson, A. K. L.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer
    Journal Article

    Scher, H. I.; Graf, R. P.; Schreiber, N. A.; Jayaram, A.; Winquist, E.; McLaughlin, B.; Lu, D.; Fleisher, M.; Orr, S.; Lowes, L.; more...
    JAMA Oncology (2018)

    Fulltext@MSK | Save
  • Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making
    Journal Article

    Abida, W.; Armenia, J.; Gopalan, A.; Brennan, R.; Walsh, M.; Barron, D.; Danila, D.; Rathkopf, D.; Morris, M.; Slovin, S.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • Baseline CTC subtype to predict outcomes on mCRPC patients (pts) receiving enzalutamide (E) compared to abiraterone (A)
    Meeting Abstract

    Scher, H. I.; Jendrisak, A.; Schreiber, N. A.; McLaughlin, B.; Graf, R. P.; Rodriguez, A.; Fleisher, M.; Lee, J.; Kelvin, J.; Wang, Y.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Changes in CTC burden and prevalence of specific CTC subtypes in mCRPC patients (pts) receiving alpharadin (Ra-223) as single agent or in combination with other therapuetics (Tx)
    Meeting Abstract

    Dittamore, R. V.; Jendrisak, A.; Schreiber, N. A.; McLaughlin, B.; Graf, R.; Rodriguez, A.; Fleisher, M.; Lee, J.; Kelvin, J.; Wang, Y.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phenotypic circulating tumor cell (CTC) classifier of genomic instability (GI) associates with improved overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving platinum agents in addition to taxanes
    Meeting Abstract

    Scher, H.; Graf, R. P.; Jendrisak, A.; McLaughlin, B.; Barnett, E.; Schreiber, N. A.; Lee, J.; Kelvin, J.; Wang, Y.; Landers, M.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Phenotypic heterogeneity of circulating tumor cells informs clinical decisions between AR signaling inhibitors and taxanes in metastatic prostate cancer
    Journal Article

    Scher, H. I.; Graf, R. P.; Schreiber, N. A.; McLaughlin, B.; Jendrisak, A.; Wang, Y.; Lee, J.; Greene, S.; Krupa, R.; Lu, D.; more...
    Cancer Research (2017)

    Fulltext@MSK | Save
  • Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer
    Journal Article

    Scher, H. I.; Graf, R. P.; Schreiber, N. A.; McLaughlin, B.; Lu, D.; Louw, J.; Danila, D. C.; Dugan, L.; Johnson, A.; Heller, G.; more...
    European Urology (2017)

    Fulltext@MSK | Save
  • AR-V7 and CTC heterogeneity biomarkers additively to predict patient (pt) outcomes with taxanes relative to approved AR targeted therapy
    Meeting Abstract

    Scher, H. I.; Graf, R.; Schreiber, N. A.; McLaughlin, B.; Lu, D.; Louw, J.; Jendrisak, A.; Greene, S.; Rodriguez, A.; Dugan, L.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save